Physician profile
Carlos E Diaz
NPI 1093797011
$6,426.55
in general payments reported to CMS, 2019-2025
27 companies · $1,374 in 2025
The $1,374 reported for 2025 was more than what a typical Glaucoma Specialist provider received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,150 · 2020: $268 · 2021: $220 · 2022: $343 · 2023: $920 · 2024: $1,151 · 2025: $1,374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,444.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,683.91 | 2019-2025 | Tecnis Simplicity, Tecnis Iol |
| Glaukos Corporation | $1,195.07 | 2019-2025 | Idose, Idosetr |
| Alcon Vision LLC | $797.24 | 2023-2025 | Clareon, Clareon Panoptix Pro, Hydrus Microstent |
| Abbvie INC. | $352.52 | 2022-2025 | Durysta |
| Mallinckrodt Hospital Products INC. | $315.05 | 2021-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $293.00 | 2019-2023 | |
| Ocular Therapeutix, INC. | $225.82 | 2023-2025 | Dextenza |
| Tarsus Pharmaceuticals, INC. | $159.22 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $157.67 | 2024 | Omni Surgical System |
| Bausch & Lomb Americas INC. | $145.51 | 2025 | Xiidra, Miebo |
| Allergan, INC. | $141.93 | 2019 | |
| Aerie Pharmaceuticals, INC. | $137.65 | 2019 | |
| Janssen Pharmaceuticals, INC | $106.39 | 2019 | |
| Rayner Intraocular Lenses Limited | $93.78 | 2024-2025 | Omidria, Rayone Spheric, Rayone Aspheric |
| New World Medical,INC. | $85.54 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $84.69 | 2019-2025 | |
| Rxsight INC | $84.03 | 2024 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Harrow Eye, LLC | $81.67 | 2024-2025 | Vevye |
| Kala Pharmaceuticals, INC. | $75.31 | 2019-2022 | |
| Amgen INC. | $59.77 | 2024-2025 | Tepezza |
| Mallinckrodt Enterprises LLC | $34.02 | 2019 | |
| Oyster Point Pharma, INC. | $28.24 | 2023 | Tyrvaya |
| Neurocrine Biosciences, INC. | $22.24 | 2019 | |
| Horizon Therapeutics Plc | $20.20 | 2023 | Tepezza |
| Alkermes, INC. | $18.79 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.88 | 2025 | Caplyta |
| Lensar, INC. | $11.41 | 2024 | Lensar Laser System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.